USA 14-01-2025WhiteHawk Capital Partners provides $350M ABL facility to Nephron PharmaceuticalsWhiteHawk Capital Partners has entered into an agreement with Nephron Pharmaceuticals to provide a US$350m asset-based credit facility. The financing will support a recapitalisation and provide liquidity for the company’s…Sign in or Upgrade to Continue ReadingThis news article is over 10 days old. Subscribe today to access all articles with an annual subscription. Become a member Learn moreAlready a subscriber? Log in here #ABL#asset based lending#WhiteHawk